Format

Send to

Choose Destination
Biosens Bioelectron. 2016 May 15;79:313-9. doi: 10.1016/j.bios.2015.12.058. Epub 2015 Dec 19.

DNA aptamer-based sandwich microfluidic assays for dual quantification and multi-glycan profiling of cancer biomarkers.

Author information

1
Department of Electronic & Electrical Engineering, University of Bath, Bath BA2 7AY, United Kingdom. Electronic address: P.Jolly@bath.ac.uk.
2
Department of Glycobiotechnology, Center for Glycomics, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, Bratislava 84105, Slovakia. Electronic address: Pavel.Damborsky@savba.sk.
3
INESC-MN - Microsystems and Nanotechnologies, R. Alves Redol 9, 1000-029 Lisboa, Portugal. Electronic address: Nsrinivasan@inesc-mn.pt.
4
INESC-MN - Microsystems and Nanotechnologies, R. Alves Redol 9, 1000-029 Lisboa, Portugal; Department of Bioengineering, Instituto Superior Técnico, University of Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal. Electronic address: Ruben.Soares@tecnico.ulisboa.pt.
5
INESC-MN - Microsystems and Nanotechnologies, R. Alves Redol 9, 1000-029 Lisboa, Portugal. Electronic address: vchu@inesc-mn.pt.
6
INESC-MN - Microsystems and Nanotechnologies, R. Alves Redol 9, 1000-029 Lisboa, Portugal; Department of Bioengineering, Instituto Superior Técnico, University of Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal. Electronic address: joao.conde@tecnico.ulisboa.pt.
7
Department of Glycobiotechnology, Center for Glycomics, Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, Bratislava 84105, Slovakia. Electronic address: Jaroslav.Katrlik@savba.sk.
8
Department of Electronic & Electrical Engineering, University of Bath, Bath BA2 7AY, United Kingdom. Electronic address: P.Estrela@bath.ac.uk.

Abstract

Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer-Antibody Assay) or a lectin (Aptamer-Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5 ng/mL of fPSA and 3 ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.

KEYWORDS:

DNA aptamer; ELISA; Glycoprofiling; Microfluidics; Prostate cancer; Sandwich assay

PMID:
26720920
DOI:
10.1016/j.bios.2015.12.058
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center